Hepatic helical CT: effect of reduction of iodine dose of intravenous contrast material on hepatic contrast enhancement

Proposal of size-based surgical indication criteria for liver hemangioma based on a nationwide survey in Japan

BACKGROUND

Surgical indications for liver hemangioma remain unclear.

METHODS

Of 510 patients undergoing surgical resection for liver hemangioma in 118 Japanese centers between 1998 and 2012, abdominal symptoms, diagnostic accuracy, and surgical outcomes were analyzed to propose size-based surgical indications. Patients were classified into four groups based on tumor size: Group A ≤5 cm (n = 122, 24%), Group B 5-10 cm (n = 164, 32%), Group C 10-15 cm (n = 124, 24%), and Group D >15 cm (n = 100, 20%).

RESULTS

Hemangiomas in Group A were most frequently diagnosed as malignant tumors (43.5%) due to the absence of typical imaging findings and with highest incidence of positive HBV (15.7%). Diagnostic accuracy was 98.4% in Groups B to D. Liver failure after hepatectomy was higher in Group D than in Groups A to C (3.0% vs. 0.5%, P = 0.02). Only one operative death was observed (0.2%) in Group D.

CONCLUSIONS

In patients with ≤5 cm hemangioma, surgical resection can be indicated when a malignant tumor cannot be ruled out. However, surgery for 5-10 cm asymptomatic hemangiomas should be limited. Experienced hepatic surgeons should conduct hepatectomy for tumors >15 cm to avoid serious morbidity or mortality.

Computed tomography: revolutionizing the practice of medicine for 40 years

Computed tomography (CT) has had a profound effect on the practice of medicine. Both the spectrum of clinical applications and the role that CT has played in enhancing the depth of our understanding of disease have been profound. Although almost 90 000 articles on CT have been published in peer-reviewed journals over the past 40 years, fewer than 5% of these have been published in Radiology. Nevertheless, these almost 4000 articles have provided a basis for many important medical advances. By enabling a deepened understanding of anatomy, physiology, and pathology, CT has facilitated key advances in the detection and management of disease. This article celebrates this breadth of scientific discovery and development by examining the impact that CT has had on the diagnosis, characterization, and management of a sampling of major health challenges, including stroke, vascular diseases, cancer, trauma, acute abdominal pain, and diffuse lung diseases, as related to key technical advances in CT and manifested in Radiology.

An optimal contrast dose indicator for the determination of hepatic enhancement in abdominal multidetector computed tomography: comparison of patient attenuation indicator with total body weight and body mass index

PURPOSE

To evaluate a patient attenuation indicator (PAI) as compared with traditional patient-related factors of total body weight and body mass index (BMI) as a predictor of hepatic enhancement in contrast-enhanced abdominal multidetector computed tomography (MDCT).

MATERIALS AND METHODS

Institutional review board approval was obtained, and the study was Health Insurance Portability and Accountability Act compliant. A total of 77 patients (mean age, 53 years; male-female ratio, 32:45) underwent routine contrast-enhanced abdominal CT on a 16-slice multidetector CT (LightSpeed 16; GE Medical Systems, Milwaukee, Wis). Contrast enhancement was achieved by administering a 120-mL iodine contrast medium (350-mg iodine per milliliter) at an injection rate of 3 mL/s followed by an injection of 40-mL saline at 3 mL/s. Computed tomographic attenuation values (Hounsfield units [HU]) of liver parenchyma, main portal vein, and abdominal aorta were measured in each patient. Statistical analysis was performed with linear regression to determine the correlation of PAI, total body weight, and BMI with abdominal organ enhancement.

RESULTS

The mean of PAI, total body weight, and BMI were 28.0 (range, 22.1-34.2), 79.0 kg (range, 49.6-112.2 kg), and 27.5 kg/m (range, 16.8-43 kg/m), respectively. Mean hepatic enhancement was 128.2 HU (range, 73.6-175 HU), mean main portal vein enhancement was 214.2 HU (range, 118-327 HU), and mean abdominal aorta enhancement was 208.9 HU (range, 116-395 HU). Patient attenuation indicator, total body weight, and BMI showed a negative correlation with liver enhancement (r = -0.55, r = -0.4, and r = -0.3, respectively). Patient attenuation indicator exhibited a significantly higher correlation with hepatic enhancement than total body weight and BMI (P < 0.01, respectively).

CONCLUSIONS

Patient attenuation indicator exhibits a moderately inverse correlation with liver enhancement that is greater than those of total body weight and BMI. Patient attenuation indicator may be reliable in predicting the hepatic enhancement degree for a given dose of contrast material and has a potential use in customizing individual patient contrast medium dose during contrast-enhanced abdominal CT.

Intravenous contrast medium administration and scan timing at CT: considerations and approaches

The continuing advances in computed tomographic (CT) technology in the past decades have provided ongoing opportunities to improve CT image quality and clinical practice and discover new clinical CT imaging applications. New CT technology, however, has introduced new challenges in clinical radiology practice. One of the challenges is with intravenous contrast medium administration and scan timing. In this article, contrast medium pharmacokinetics and patient, contrast medium, and CT scanning factors associated with contrast enhancement and scan timing are presented and discussed. Published data from clinical studies of contrast medium and physiology are reviewed and interpreted. Computer simulation data are analyzed to provide an in-depth analysis of various factors associated with contrast enhancement and scan timing. On the basis of basic principles and analysis of the factors, clinical considerations and modifications to protocol design that are necessary to optimize contrast enhancement for common clinical CT applications are proposed.

Aortic and hepatic contrast enhancement with abdominal 64-MDCT in pediatric patients: effect of body weight and iodine dose

OBJECTIVE

The purpose of our study was to retrospectively evaluate the effect of body weight and iodine dose on aortic and hepatic contrast enhancement in pediatric patients who underwent 64-MDCT of the abdomen and pelvis.

MATERIALS AND METHODS

Eighty-seven consecutive pediatric patients (50 boys and 37 girls; median age, 12.1 years; age range, 3.8-17.6 years) underwent standard abdominopelvic CT with a 64-MDCT scanner. Contrast medium (350 mg I/mL) was injected using a power injector at 2 mL/s followed by 15-20 mL of saline flush. According to our CT protocol, the volume of administered contrast medium was approximately 1.8 mL/kg of body weight, up to the maximum volume of 80 mL. CT scanning was initiated 60 seconds after the start of the contrast medium injection. CT attenuations of the aorta and liver were measured. For each patient, the injected contrast medium iodine mass per body weight index (g I/kg) (hereafter, iodine mass body index) was calculated. Linear regression analysis was performed between iodine mass body index and aortic and hepatic attenuations.

RESULTS

A wide range of patient weights (19-82 kg; mean, 48.6 kg [95% CI, 45.3-51.9 kg]) and contrast volumes (30-80 mL; median, 80.0 mL) were observed. The median attenuations were 149.0 HU (141.0-160.0 HU) for the aorta and 113.5 HU (109.5-120.0 HU) for the liver. Moderately high correlations were observed between iodine mass body index and aortic (Spearman's rho [r(s)] = 0.60 [0.45-0.72]; p < 0.001) and hepatic (r(s) = 0.60 [0.42-0.70]; p < 0.001) attenuations. The regression formulae for aortic attenuation (58.4 + 176.3 x iodine mass body index [p < 0.001]) and hepatic attenuation (58.7 + 108.5 x iodine mass body index [p < 0.001]) indicate that 1.5 and 1.8 mL/kg (350 mg I/mL) of contrast media are required to achieve 116 and 127 HU, respectively, of contrast-enhanced attenuation in the liver.

CONCLUSION

In our study, using abdominal 64-MDCT in pediatric patients, we found that approximately 1.5 mL/kg, or 0.525 g I/kg, yields 116 HU of hepatic attenuation or 50-55 HU of hepatic enhancement.

Pancreatic adenocarcinoma: analysis of the effect of various concentrations of contrast material

PURPOSE

The aim of this study was to compare the efficacy of two contrast materials with moderate and high iodine concentrations for the depiction of pancreatic adenocarcinoma.

MATERIALS AND METHODS

A series of 107 patients with histologically proven pancreatic adenocarcinoma underwent helical computed tomography. A fixed dose of 100 ml of iopamidol 300 (mg I/ml) was administered to 50 patients (group A) and iopamidol 370 (mg I/ml) to 57 patients (group B) at the same injection rate (3 ml/s). Unenhanced helical scans and contrast-enhanced scans for three phases (30, 70, and 300 s after starting the infusion of contrast material) were obtained. We evaluated enhancement of the aorta, portal vein, hepatic parenchyma, pancreatic parenchyma, and pancreatic adenocarcinoma during each phase.

RESULTS

During all phases, both aortic and pancreatic enhancement were significantly greater in group B than in group A (P<0.01). Enhancement of the portal vein and hepatic parenchyma was significantly greater at 70 and 300 s in group B than in group A (both P<0.01). Tumor-to-pancreas contrast was significantly greater in group B than in group A at both 30 s (P<0.01) and 70 s (P<0.05).

CONCLUSION

Administration of contrast material with a high iodine concentration is more effective for depicting pancreatic adenocarcinomas.

Management of liver hemangiomas according to size and symptoms

BACKGROUND AND AIM

Liver hemangiomas are the most common benign liver tumors. These lesions are usually incidental findings during imaging studies of the abdomen performed for other reasons. The indication for surgical resection of these lesions remains controversial.

METHODS

Records of patients referred for evaluation of radiologically and/or histopathologically proven liver hemangiomas, from June 1991 to February 2006, were retrospectively analyzed. Reason for referral, results of imaging studies, and surgical treatment and outcome were reviewed.

RESULTS

There were 34 patients identified. The hemangioma size was <5 cm in 15 patients (44%) and >5 cm in 19 patients. The most common reason for referral was right upper abdominal pain in 59% (20/34) of patients. Abdominal ultrasound was conclusive in 66.7% (16/24) and four-phase computed tomography (CT) in 82.6% (19/23) of patients. Surgical resection was undertaken in 14 patients (41%) after a mean follow-up time of 36.5 months. The indication for treatment was progressive abdominal pain in 78.6% (11/14). Mean size of resected lesions was larger compared to non-resected lesions (10.3 vs 4.8 cm; P = 0.004). Postoperative morbidity occurred in three patients (21.4%). One patient had persisting abdominal pain after resection of an 8-cm hemangioma. Twenty patients were observed and showed no complications related to the liver hemangioma during follow-up.

CONCLUSIONS

Liver hemangiomas can be readily diagnosed by ultrasound or multiphase contrast-enhanced helical CT. The indications for surgical resection are progressive abdominal pain in combination with size >5 cm. Observation is justified in patients with minimal or no symptoms, even in patients with giant hemangiomas.

Radiological staging of colorectal liver metastases

Rapid advances in imaging technology have improved the detection, characterization and staging of colorectal liver metastases. Multi-modality imaging approach is usually the more useful in staging colorectal liver metastases. Multi-detector computed tomography (MDCT) remains the main imaging modality for preoperative planning, lesion detection and tumour surveillance. Magnetic resonance imaging (MRI) and contrast enhanced ultrasonography (US) are invaluable in problem solving for characterization indeterminate lesions, while contrast enhanced intra-operative ultrasound (CE-IOUS) may be the new gold standard staging tool prior to liver resection. Ultimately, the imaging strategy has to be tailored to the clinical situation to obtain the most relevant information for optimal use of available imaging resources.

IV Contrast Selection for MDCT: Current Thoughts and Practice

OBJECTIVE

The purpose of this article is to review studies evaluating how contrast concentration affects MDCT of the body and to report IV contrast infusion protocols from MDCT angiography and MDCT of abdominal tumors.

CONCLUSION

Higher concentrations (350 mg I/mL or greater) may improve visualization of small abdominal arteries. However, preliminary data comparing 300 mg I/mL to higher concentrations for MDCT of hypervascular hepatocellular carcinoma and pancreatic cancer have shown that higher concentrations may not increase tumor conspicuity.

Does iodine concentration affect the diagnostic efficacy of biphasic spiral CT in patients with hepatocellular carcinoma?

BACKGROUND

We investigated the effect of iodinated contrast medium concentration on increased neoplastic lesion enhancement and its direct relation to diagnostic efficacy in biphasic spiral computed tomography for detection of hepatocellular carcinoma.

METHODS

A pilot, single-center, randomized, double-blind, crossover, comparative study was performed and included 22 participants. Each patient underwent two separate biphasic contrast-enhanced spiral computed tomographic examinations. Scans were performed with iomeprol containing 400 (iomeprol 400) or 300 (iomeprol 300) mg of iodine per milliliter (Iomeron, Bracco Imaging SpA, Milan, Italy) with a 2- to 12-day window scan; patients were given an equal total dose of 45 g of iodine at a fixed injection rate of 4 mL/s. Comparison included assessment of quantitative and qualitative parameters.

RESULTS

Lesion density and lesion-to-liver contrast increased more markedly with the higher concentration of contrast medium during the arterial phase (p = 0.0016 and 0.0005, respectively). There was no significant difference in any parameter between the two concentrations during the portal phase. Number of lesions detected during the arterial phase increased from 37 with iomeprol 300 to 42 with iomeprol 400; in the portal phase, the respective numbers were 34 and 36.

CONCLUSION

Even though a small number of patients was examined, our study suggests that, in patients with cirrhosis, an increased concentration of iodine improves liver-to-lesion contrast and may improve the detection of hepatocellular carcinoma.

High-Concentration Contrast Media in Multiphasic Abdominal Multidetector-Row Computed Tomography

OBJECTIVE

The purpose of this study was to assess the influence of the iodine flow rate on parenchymal and vascular enhancement during multiphasic abdominal multidetector-row computed tomography (MDCT).

METHODS

Fifteen patients underwent MDCT at an iodine flow rate of 1.2 g/s as well as 1.6 g/s (group A, protocols 1 and 2), and 90 patients underwent MDCT at an iodine flow rate of 1.2 g/s (group B) or 1.6 g/s (group C). Measurements were performed for all groups in the liver, spleen, pancreas, portal vein, inferior vena cava, and abdominal aorta.

RESULTS

Aortal and pancreatic enhancement during the arterial phase was significantly higher with the higher iodine flow rate. The mean difference in aortal enhancement was 60 Hounsfield units (HU) between protocols 1 and 2 of group A, and the mean difference was 70 HU between groups B and C. The mean difference in pancreatic enhancement was 10 HU between protocols 1 and 2 of group A and 17 HU between groups B and C. During the portal and hepatic venous phases, no significant difference in enhancement was observed.

CONCLUSION

A high iodine flow rate in multiphasic abdominal MDCT improves enhancement of the aorta and the pancreas during the arterial phase but does not influence later phases.

Effect of iodine concentration of contrast media on contrast enhancement in multislice CT of the pancreas

The purpose of this study was to determine the influence of two different iodine concentrations of the non-ionic contrast agent, Iomeprol, on contrast enhancement in multislice CT (MSCT) of the pancreas. To achieve this MSCT of the pancreas was performed in 50 patients (mean age 57+/-14 years) with suspected or known pancreatic tumours. The patients were randomly assigned to group A (n=25 patients) or group B (n=25 patients). There were no statistically significant differences in age, height or weight between the patients of the two groups. The contrast agent, Iomeprol, was injected with iodine concentrations of 300 mg ml(-1) in group A (130 ml, injection rate 5 ml s(-1)) and 400 mg ml(-1) in group B (98 ml, injection rate 5 ml s(-1)). Arterial and portal venous phase contrast enhancement (HU) of the vessels, organs, and pancreatic masses were measured and a qualitative image assessment was performed by two independent readers. In the arterial phase, Iomeprol 400 led to a significantly greater enhancement in the aorta, superior mesenteric artery, coeliac trunk, pancreas, pancreatic carcinomas, kidneys, spleen and wall of the small intestine than Iomeprol 300. Portal venous phase enhancement was significantly greater in the pancreas, pancreatic carcinomas, wall of the small intestine and portal vein with Iomeprol 400. The two independent readers considered Iomeprol 400 superior over Iomeprol 300 concerning technical quality, contribution of the contrast agent to the diagnostic value, and evaluability of vessels in the arterial phase. No differences were found for tumour delineation and evaluability of infiltration of organs adjacent to the pancreas between the two iodine concentrations. In conclusion the higher iodine concentration leads to a higher arterial phase contrast enhancement of large and small arteries in MSCT of the pancreas and therefore improves the evaluability of vessels in the arterial phase.

Multidetector helical computed tomography of the liver: comparison of hepatic enhancement using two different contrast media strategies

RATIONALE AND OBJECTIVES

The purpose of this study was to compare hepatic enhancement characteristics using two different contrast media injection protocols with multidetector helical computed tomography.

MATERIALS AND METHODS

Twenty-three patients with known or suspected liver lesions scheduled to undergo biphasic hepatic multidetector helical computed tomography were randomized into one of two groups: (1) 150 mL of iopamidol (300 mgI/mL) at 5 mL/second, or (2) 100 mL of iopamidol (370 mgI/mL) at 4 mL/second. Unenhanced images were acquired initially, followed by both hepatic arterial phase (scan delay, 33 seconds) and portal venous phase (PVP; scan delay, 65 seconds) imaging. Three abdominal radiologists independently graded the images on a scale from 1-5 for enhancement and overall scan quality. Time-attenuation curves were generated from operator-defined region-of-interest measurements of liver parenchyma and aorta.

RESULTS

Qualitatively, the three reviewers found no significant difference between the two study groups in terms of overall scan quality (P = .23) or aortic enhancement (hepatic arterial phase, P = .9; PVP, P = .24). However, liver enhancement during the PVP was considered to be less in the Isovue 370 group (P = .04). Quantitatively, during the hepatic arterial phase, there was no statistically significant difference between the two injection protocols comparing either aortic or hepatic parenchymal enhancement (P = .62 and .80, respectively). During the PVP, these differences were statistically significant, with both aortic and hepatic parenchymal enhancement lower in the Isovue 370 group (P < .01 and P = .04, respectively).

CONCLUSION

It is important to consider the amount of iodine injected per second and the duration of the injection when setting up protocols to achieve target organ enhancement. 100 mL of iopamidol 370 at 4 mL/second can be used to obtain images of the liver with good diagnostic quality compared to more conventional protocols using 150 mL of iopamidol 300 at 5 mL/second. However, the degree of liver parenchymal enhancement during the PVP using the latter injection scheme is lower, which in turn could potentially reduce hepatic lesion conspicuity.

Impact of multislice CT on imaging of acute abdominal disease

The increased speed, greater coverage, and thinner slices of MSCT are exciting developments in radiology, and these feature should only improve with newer generation multislice scanners. The impact of this technology on abdominal imaging has just begun.

Abdominal multidetector row computed tomography: reduction of cost and contrast material dose using saline flush

OBJECTIVE

To evaluate the potential of a saline solution flush after the contrast material bolus in abdominal multidetector row CT (MDCT) in contrast material dose and cost reduction.

METHODS

Abdominal MDCT was performed in 78 patients who were assigned randomly to 2 groups receiving 120 mL nonionic contrast material (300 mgI/mL) alone or 100 mL of the same contrast material pushed with 40 mL of saline solution. Mean attenuation values for both groups were measured in the liver, the spleen, the pancreas, the portal vein, the inferior vena cava, and the abdominal aorta. Cost analyses were performed for both groups.

RESULTS

There was no significant difference in parenchymal and vascular enhancement between both groups. The difference of the enhancement was 2 HU for the liver (P = 0.11), 2 HU for the spleen (P = 0.44), 3 HU for the pancreas (P = 0.38), 9 HU for the portal vein (P = 0.11), 3 HU for the inferior vena cava (P = 0.55), and 10 HU for the aorta (P = 0.06). Taking the costs of contrast material, saline solution, and disposal material into account, 7.30 dollars was saved by the patient using a saline solution flush.

CONCLUSIONS

Using a saline flush after the contrast material bolus in abdominal MDCT allows an iodine dose reduction of approximately 6 g, or 17%, without impairing mean parenchymal and vascular enhancement and a cost reduction of 7.30 dollars per patient.

Improvement of parenchymal and vascular enhancement using saline flush and power injection for multiple-detector-row abdominal CT

The aim of this study was to determine if a saline solution flush following low dose contrast material bolus improves parenchymal and vascular enhancement during abdominal multiple detector-row computed tomography (MDCT). Forty-one patients (24 men and 17 women; mean age 49 years, age range 27-86 years) underwent abdominal MDCT (collimation 4x5 mm, 15-mm table increment, reconstruction interval 5 mm, gantry rotation period 0.8 s) with a single- as well as with a double syringe power injector. Indication for examination were benign and malignant tumors and inflammatory diseases. Patients received 100 ml nonionic contrast material (300 mgI/ml) alone or pushed with 20 ml saline solution. Mean enhancement values for both protocols were measured in the liver, the spleen, the pancreas, the renal cortex, the portal vein, the inferior vena cava and the abdominal aorta. Double syringe power-injector protocol led to significantly higher parenchymal and vascular enhancement than single syringe power-injector protocol (p<0.05). The improvement in mean enhancement of the liver was 9 +/- 9 HU, of the spleen 8 +/- 10 HU, of the pancreas 7 +/- 9 HU, and of the renal cortex 8 +/- 20 HU. The improvement in mean enhancement of the portal vein was 10 +/- 17 HU of the inferior vena cava 8 +/- 13 HU and of the abdominal aorta 10 +/- 17 HU. The use of a double syringe power injector with saline flush following contrast material bolus significantly improves parenchymal and vascular enhancement during contrast-enhanced abdominal MDCT with low iodine doses.

Diagnosis, management, and outcomes of 115 patients with hepatic hemangioma

BACKGROUND

Hepatic hemangiomas are congenital vascular malformations and are the most common benign hepatic tumors. Because the use of cross-sectional imaging has increased, benign hepatic tumors, especially hemangiomas, are encountered more frequently, so clinicians should be familiar with the most appropriate diagnostic tests, management, and outcomes of patients with hepatic hemangioma.

STUDY DESIGN

All patients with a primary diagnosis of hepatic hemangioma referred for surgical evaluation at our institution between January 1992 and December 2000 were identified from a prospective database. Demographics, presentation, tumor characteristics, diagnostic studies, surgical procedures, and outcomes were analyzed. RESULTS; Of 115 patients in the study, nearly half were asymptomatic. In symptomatic patients, abdominal pain or discomfort was the most common presenting symptom. At our institution, the diagnosis of hemangioma was established by ultrasonographic studies in 57% of patients tested, by CT scan in 73%, and by MRI in 84%. In patients with large tumors considered for resection, direct angiography or, more recently, CT angiography, confirmed the diagnosis in 27 of 29 patients (93%). Enucleation was performed in 31 (60%) of the 52 patients who underwent surgical resection; 63 patients were observed. Postoperative complications occurred in 13 patients (25%), and there were no perioperative deaths. Of the patients with symptoms before resection, 96% had resolution of symptoms after operation.

CONCLUSIONS

Hepatic hemangioma can be diagnosed in most patients using noninvasive studies, particularly MRI. Hepatic hemangiomas can be removed safely if patients become symptomatic or when malignancy cannot be excluded. CT angiography can be a valuable preoperative study in patients with large tumors, and enucleation is the procedure of choice. In asymptomatic or minimally symptomatic patients, hepatic hemangiomas usually have a benign course and can be observed.

Selective use of low-osmolality contrast media in computed tomography

The aim of this study was to describe our experience and institutional savings with a selective use of low-osmolality contrast media (LOCM) in CT. From 1995 to 1998, a total of 19,834 contrast-enhanced CT examinations were performed at our institution. Contrast was injected with a power injector and large venous catheter, 20-G for 2- to 3-ml rate and 18-G for 3- to 5-ml rate. High-osmolality contrast media was used in 13,670 patients (71%). The LOCM was used in 5884 (29%) patients. Our guidelines for the use of LOCM included cardiac dysfunction, severe pulmonary impairment, history of allergy or prior moderate reaction to HOCM and severe debilitation. Prior to the injection of HOCM, 10 mg of metoclopramide (Primperan, Delagrange Quétigny, France) were administered to reduce nausea and vomiting. In the HOCM group there were 304 minor or mild adverse reactions (2.2%), and 10 severe adverse reactions (0.08%). In the LOCM there were 34 mild or moderate adverse reactions (0.59%) and 3 severe adverse reactions (0.05%). Significant differences in terms of mild adverse reactions were found between HOCM and LOCM (Fischer's test, p<0.001). No significant differences were found in terms of severe adverse reactions ( p=0.27). After subtracting the cost of treating additional adverse reactions, the net differential cost between universal and selective use of LOCM was 565,285 Euro (601,067 US dollars). This means a net increase of 41.4 Euro per patient or 414,000 Euro per 10,000 patients (438,840 US dollars). Selective use of LOCM in CT is safe and effective and results in a substantial reduction in costs.

1-molar gadobutrol as a contrast agent for computed tomography: results from a comparative porcine study

RATIONALE AND OBJECTIVES

To evaluate prospectively the efficacy of gadobutrol as contrast agent for computed tomography (CT) compared with iodinated contrast media in a porcine animal model.

METHODS

In 8 domestic pigs (35 +/- 4 kg body weight [BW]), continuous spiral CTs of the chest and abdomen were performed using either 2 mmol/kg BW Gadovist 1.0 (1 mol/L gadobutrol) intravenously or Ultravist (300 mg I/mL iopromide) (slice 5 mm, table feed 7.5 mm, reconstruction increment 5 mm). One week later, the same animals were examined using the same protocol with the other contrast agent. In 2 additional animals, serial CTs were performed at the same level using gadobutrol or iopromide on day 1 and the alternate agent on day 8 inches order to determine contrast media kinetics, peak enhancement, and time enhancement-product in important vascular regions and parenchymal organs (abdominal aorta, inferior vena cava, liver, and renal parenchyma). Peak enhancement (net increase compared with nonenhanced baseline values) was measured in Hounsfield units (HU) in defined regions of interest.

RESULTS

In vivo, the mean peak enhancement 5, 15, 30, and 120 seconds in the abdominal aorta after injection of 2 mL/kg BW gadobutrol and iopromide was 200 +/- 11, 224 +/- 10, 261 +/- 13, and 95 +/- 9 HU versus 232 +/- 10, 298 +/- 10, 152 +/- 11, and 123 +/- 10 HU, respectively. Differences in enhancement of vascular structures was statistically significant (P < 0.05) in carotid arteries (235 +/- 20 HU for gadobutrol and 264 +/- 19 HU for iopromide) and the aortic arch (261 +/- 14 HU for gadobutrol and 279 HU +/- 13 HU for iopromide). No statistical significance was seen in all other measured vascular structures and parenchymal organs.

CONCLUSION

Contrast-enhanced CT with 1 mol/L gadobutrol in a dose of 2 mmol/kg BW resulted in an excellent vascular and parenchymal enhancement in most vascular regions and parenchymal organs similar to an equivalent volume of 300 mg/mL iodinated contrast media.

Using a saline chaser to decrease contrast media in abdominal CT

OBJECTIVE

The purpose of this study was to compare hepatic tumor conspicuity on CT after injection of either 150 mL of contrast material or 100 mL of contrast material plus a 50-mL saline chaser.

SUBJECTS AND METHODS

We evaluated 86 hypoattenuating liver metastases in 26 patients. Patients underwent CT in two sessions separated by a mean of 85 days: one time with 150 mL of contrast material and the other time with 100 mL of contrast material followed by a 50-mL saline chaser. The order of the sessions was randomized. Contrast material was administered via power injector and matched for injection rate and delay time. Attenuation values were obtained from normal liver tissue and metastases and from the spleen, kidney, aorta, and inferior vena cava.

RESULTS

The 150 mL dose of contrast material caused slightly greater liver and tumor attenuation than 100 mL of contrast material with a chaser (mean hepatic attenuation, 95.6 vs 89.8 H, respectively; p < 0.03, paired t test; mean tumor attenuation, 53.2 vs 49.1 H, respectively; r = 0.71, p = 0.09). The difference in conspicuity of liver lesions was slightly greater with 150 mL than with 100 mL with a chaser (46.8 H vs 44.2 H; r = 0.46, p = 0.08, paired t test), but was of doubtful clinical significance (2.6 H). Kidney, spleen, and vascular structures enhanced more with 150 mL than with 100 mL and a chaser.

CONCLUSION

Using 100 mL of contrast material and a saline chaser did not result in a meaningful difference in liver parenchyma attenuation or lesion conspicuity compared with using 150 mL of contrast medium alone. Routine use of a chaser for abdominal CT may yield cost savings and a decreased risk of contrast nephropathy.

Current techniques of computed tomography. Helical CT, multidetector CT, and 3D reconstruction

The many recent advances in CT technology have secured its position as the modality of choice in routine liver imaging and have improved its performance in several problem-solving applications. In addition, improvements in postprocessing software (e.g., in speed, efficiency, and automated algorithms) have increased their use in clinical practice. Multiplanar reformations, 3D renderings, and high-quality CT angiographic displays have become extremely valuable both in image interpretation and in communicating information to surgeons and referring physicians.

Quantitative and qualitative evaluation of volume of low osmolality contrast medium needed for routine helical abdominal CT

OBJECTIVE

The purpose of our study was to determine the minimum optimal dose of IV contrast medium for helical CT that can preserve image quality while reducing cost.

SUBJECTS AND METHODS

Four hundred sixty-three patients from six centers were enrolled in a prospective trial in which patients were randomized into one of four weight-based dose categories of iopromide, 300 mg I/mL: 1.25, 1.50, 1.75, and 2.0 mL/kg. Six of 463 patients were excluded from analysis. A radiologist at each center who was unaware of the volume of contrast medium administered determined whether the scans were acceptable. The responses were analyzed by dose, in aggregate, and by weight. Enhancement values (in Hounsfield units) in regions of interest in the liver, pancreas, aorta, and kidneys were obtained at a single time during the scan. The participating radiologist was unaware of these values. Finally, three additional nonparticipating site observers assessed the images for acceptability, diagnostic quality, and overall level of confidence. A cost model comparing incurred charges in using 150 or 100 mL, or 1.5 mL/kg, of low osmolality contrast medium was developed from experience in an additional 303 patients.

RESULTS

We found no clinically significant difference in acceptability of scans at doses greater than 1.5 mL/kg. However, significant variability occurred among the centers. The use of 1.5 mL/kg led to a savings of $9927.16 for 303 patients when compared with the use of 150 mL at list price. The cost is the same for 1.5 mL/kg or use of 100 mL of contrast medium.

CONCLUSION

A weight-based dose at 1.5 mL/kg of low osmolality contrast medium can provide acceptable scans in most patients, with a significant cost savings.

Abdominal helical CT: evaluation of optimal doses of intravenous contrast material--a prospective randomized study

PURPOSE

To determine the optimal dose of intravenous contrast material for helical computed tomography (CT) of the abdomen on the basis of patient weight.

MATERIALS AND METHODS

A prospective randomized study of helical CT of the abdomen was performed by using different doses of intravenous contrast material in 221 patients (mean body weight, 57.3 kg) who were assigned randomly to three groups receiving 1.5, 2.0, or 2.5 mL/kg or a fixed dose of 100 mL of iopamidol 300. The degree of enhancement was scored visually. The CT numbers (HU) of the aorta, portal vein, liver, and pancreas were obtained at three levels of the abdomen.

RESULTS

In arterial enhancement, the 2.0 mL/kg, 2.5 mL/kg, and fixed-dose groups were significantly better than the 1.5 mL/kg group, but there was no significant difference among the 2.0 mL/kg, 2.5 mL/kg, or fixed-dose groups. The degree of enhancement of the liver, pancreas, and portal vein increased with larger doses. At visual analysis, hepatic parenchymal enhancement was graded as good or excellent in 64% of the 1.5 mL/kg, 85% of the 2.0 mL/kg, 94% of the 2.5 mL/kg, and 65% of the fixed-dose groups.

CONCLUSION

When dose was tailored to patient weight, the use of 2.0-2.5 mL/kg of intravenous contrast material produced better results than did 1.5 mL/kg or a fixed dose. Arterial enhancement did not differ among the 2.0 mL/kg, 2.5 mL/kg, or fixed-dose groups.

Detection of focal liver lesions at biphasic spiral CT: randomized double-blind study of the effect of iodine concentration in contrast materials

PURPOSE

To evaluate the effect of iodine concentration on the detection of focal liver lesions at biphasic spiral computed tomography (CT).

MATERIALS AND METHODS

One hundred two patients (64 men, 38 women) with neoplastic (n = 85) and nonneoplastic focal lesions (n = 17) were prospectively assigned to biphasic injection group A or B and received 180 mL of iopromide containing 370 or 300 mg of iodine per milliliter, respectively, during spiral CT. Comparison included assessment of quantitative and qualitative parameters.

RESULTS

Hepatic time-attenuation curves and mean hepatic enhancement in the portal venous phase and aortic time-attenuation curves in both arterial and portal venous phases were statistically superior in group A compared with group B. There was no significant difference in the mean enhancement in all lesions in either group. In contrast, among patients with hepatocellular carcinoma, mean contrast enhancement in lesions in the arterial phase was significantly superior in group A compared with group B. Blinded readers classified hepatic attenuation and lesion visibility as very good and as improved significantly more often in group A than in group B.

CONCLUSION

A decrease in iodine concentration significantly affects aortic and hepatic contrast enhancement and may impair the detectability of focal liver lesions during biphasic spiral CT.

Factors influencing vascular and hepatic enhancement at CT: experimental study on injection protocol using a canine model

PURPOSE

The purpose of this work was to evaluate the effects of contrast medium injection parameters on aortic, portal vein, and hepatic enhancement at spiral CT and to assess optimal injection protocol for hepatic CT.

METHOD

Ten 15 kg dogs underwent single level dynamic CT through the hepatic hilum at 5 s intervals just after the injection of contrast medium for 3 min. With use of different volumes (1, 2, and 3 ml/kg), injection rates (0.5, 1, and 2 ml/s), and concentrations (150, 200, and 300 mg/ml), a total of 270 spiral CT scans were performed. In each scan, time-attenuation curves of aorta, portal vein, and liver were obtained. The degree of maximum contrast enhancement (Imax), time to maximum enhancement (Tmax), and time to equilibrium phase (Teq) for to each injection protocol were analyzed.

RESULTS

Alterations in contrast material volume, injection rate, and concentration had significant impact on contrast enhancement of the liver. With increasing volume of contrast medium, Imax, Tmax, and Teq of aorta, portal vein, and liver increased (p < 0.005). With increasing rate of injection, on the other hand, Imax of aorta and liver increased (p < 0.05), but Tmax and Teq decreased (p < 0.005). Change of concentration of contrast medium had a significant effect on Imax of vessels (p < 0.05).

CONCLUSION

Maximum contrast enhancement of liver and vessels was influenced mainly by injection volume of contrast medium and the time to peak enhancement by injection rate of contrast medium. Under given amounts of contrast medium, therefore, the strategy of increasing volume by dilution and faster injection might give better Imax values without penalty for the duration of an optimal temporal window (Tmax and Teq).

Helical CT of the liver with computer-assisted bolus-tracking technology: scan delay of arterial phase scanning and effect of flow rates

PURPOSE

The purpose of this work was to assess the scan delay and the effect of flow rates on arterial phase scanning of hepatic CT.

METHOD

One hundred twenty patients suspected of having hepatocellular carcinoma were examined by three-phase helical CT using computer-assisted bolus-tracking technology. We set the region of interest (ROI) in the abdominal aorta at the level of the celiac artery as a baseline. The triggering threshold was set at 100 HU. A volume of 100 ml of iomeprol (350 mg of I/ml) was administered at 2, 2.5, or 3 ml/s i.v.

RESULTS

In all cases, helical CT scanning began after reaching the ROI threshold. Then, portal venous phase scanning was initiated 50 s after arterial phase initiation. The mean delay time from the initiation of contrast agent administration to the beginning of arterial phase scanning was 29.2 +/- 3.8 s (mean +/- SD, range 22-39 s). A faster injection rate significantly shortened the scan delay (p < 0.01). In portal venous phase scanning, calculated areas under the hepatic enhancement curves were almost equal among different injection rates.

CONCLUSION

The computer-assisted bolus-tracking technology is a useful method for determining an individual scan delay of arterial phase CT.

Spiral CT of colon cancer: imaging features and role in management

Colorectal cancer is a common malignancy that results in significant morbidity and mortality. Abdominal computed tomography (CT) is valuable in planning surgery for colon cancer because it can demonstrate regional extension of tumor as well as adenopathy and distant metastases. At CT, colorectal cancer typically appears as a discrete soft-tissue mass that narrows the colonic lumen. Colorectal cancer can also manifest as focal colonic wall thickening and luminal narrowing. Complications of primary colonic malignancies such as obstruction, perforation, and fistula can be readily visualized with CT. At CT, local extension of tumor appears as an extracolic mass or simply as thickening and infiltration of pericolic fat. Extracolic spread is also suggested by loss of fat planes between the colon and adjacent organs. The liver is the predominant organ to be involved with metastases from colorectal cancer. At CT, hepatic metastases usually appear as hypoattenuating masses, which are best visualized during the portal venous phase of liver enhancement. Other common sites of metastases from colon cancer include the lungs, adrenal glands, and bones. Use of CT is critical for identifying recurrences, evaluating anatomic relationships, documenting "normal" postoperative anatomy, and confirming the absence of new lesions during and after therapy.

1999 ARRS Executive Council Award. Contrast-enhanced CT of small hypovascular hepatic tumors: effect of lesion enhancement on conspicuity in rabbits. American Roentgen Ray Society

OBJECTIVE

The purpose of this study was to evaluate the effect of lesion enhancement on the conspicuity of small hypovascular hepatic tumors in an animal model.

MATERIALS AND METHODS

Seven VX2 hepatic tumors in five rabbits were imaged. Dynamic contrast-enhanced CT was performed at a single level centered over the lesions at 5-sec intervals for 119 sec after injection of 2 ml/kg i.v. contrast material at 2 ml/sec. Attenuation was measured over time within regions of interest in the tumor and normal liver, aorta, inferior vena cava, and portal vein. Lesion conspicuity, defined as the difference between the attenuation of the uninvolved liver and neoplasm, was calculated.

RESULTS

The mean diameter of the tumors on CT was 10 mm (range, 6-15 mm). The tumors appeared as low-attenuation lesions with progressive enhancement during the arterial phase and early portal phase. Peak mean lesion attenuation was 60 +/- 27 H (enhancement, 23 H) at 64 sec. Peak mean lesion conspicuity was 80 +/- 18 H at 39 sec, occurring 10 sec before the peak mean hepatic attenuation of 135 +/- 15 H (enhancement, 67 H) at 49 sec. Relative lesion conspicuity paralleled relative enhancement of the liver throughout the imaging period.

CONCLUSION

Although low-level tumor enhancement during the arterial phase and early portal phase reduced the conspicuity of small hypovascular tumors in this animal model, our results support the use of maximum liver enhancement as a marker for peak lesion conspicuity.

Effective contrast use in CT angiography and dual-phase hepatic CT performed with a subsecond scanner

OBJECTIVE

To deduce an optimal injection protocol for CT angiography and fast dual-phase hepatic CT.

METHODS

Fifty-two patients underwent fast dual-phase hepatic CT using one of three different injection protocols: A (0.9 g/sec iodine injection rate, 36 g dose); B (1.35 g/sec, 30 g); C (1.6 g/sec, 40 g). Aortic attenuation time curves as well as aorta-to-liver contrast and hepatic enhancement time curves obtained by region of interest measurements along the helical axis were analyzed.

RESULTS

Protocol C revealed a significantly higher peak in aortic attenuation and hepatic enhancement than the other protocols. Approximately 50 seconds after the bolus injection, hepatic enhancement declined to a plateau similar to that seen with the other protocols. In terms of the areas under the curves of the aorta-to-liver contrast and hepatic enhancement dynamics, protocol C was significantly superior to the other protocols.

CONCLUSIONS

A high iodine injection rate realized by a high iodine concentration in conjunction with fast dual-phase scanning (total scan time < 50 seconds) promises to enhance CT angiography and contrast of liver lesions.

Gadolinium as a CT contrast agent: assessment in a porcine model

PURPOSE

To investigate the use of gadolinium as a computed tomographic (CT) contrast agent.

MATERIALS AND METHODS

In vitro attenuation measurements of multiple dilutions of gadodiamide and ioversol were compared. In three pigs, 50-mL boluses of undiluted gadodiamide were injected intravenously at 2 mL/sec, and repeated single-level scans were obtained through the lung bases, liver, and kidneys. The doses of 0.8-1.0 mmol of gadolinium per kilogram of body weight were approximately three times the highest doses currently used in patients. Enhancement was determined from attenuation measurements in the aorta, pulmonary arteries, liver, and kidneys.

RESULTS

In vitro, the attenuation of undiluted gadodiamide (3,069 HU) was equivalent to that of ioversol diluted to 106 mg of iodine per milliliter and at equimolar concentrations was 50% greater than that of ioversol. The magnitude of and time to peak enhancement were 141 HU and 27 seconds (n = 3) for the aorta; 168 HU and 21 seconds (n = 3) for the pulmonary arteries; 23 HU and 65 seconds (n = 2) for the liver; and 63 HU and 32 seconds (n = 1) for the kidneys. Time-attenuation curves revealed a useful duration of enhancement of 20-30 seconds for the aorta and pulmonary arteries.

CONCLUSION

Gadolinium produces good vascular enhancement, adequate renal enhancement, and suboptimal hepatic enhancement. Further study is needed to determine the safety of the gadolinium dose required to produce similar enhancement in patients.

Optimizing contrast enhancement during helical CT of the liver: a comparison of two bolus tracking techniques

OBJECTIVE

The purpose of this study was to evaluate a recently developed hardware and software system for CT scanning that generates images in real time and switches to helical CT scanning by either a visual cue or a region of interest (ROI) amplitude threshold.

SUBJECTS AND METHODS

We randomly and prospectively divided 120 abdominal CT examinations into three groups. Two groups received 75 ml of contrast agent at 1.5 ml/sec. Helical CT scanning began after visualization of the contrast bolus arrival in the hepatic veins (visual cue triggering) (39 patients) or after reaching an ROI threshold (automated ROI threshold triggering) (39 patients). A third group served as a control group (42 patients) and received 150 ml of contrast agent at 1 ml/sec. Quality of hepatic enhancement was assessed objectively and subjectively. Comparisons were made after stratifying each group into three weight classes.

RESULTS

Errors occurred in 12 (31%) of 39 examinations in the group with automated ROI threshold triggering. In that group, we found a significantly (p < .04) lower mean hepatic enhancement in two of three weight categories, and a significantly (p < .04) lower mean subjective scan quality in one of three weight categories, than we found in the group with visual cue triggering.

CONCLUSION

Optimizing portal venous phase helical CT of the liver after a low-volume bolus of contrast agent and an injection rate of 1.5 ml/sec is best achieved by initiating helical CT scanning after visualizing the contrast bolus arrival within the liver rather than after reaching a preset attenuation threshold.

Hepatic metastases

Developments in ultrasound, CT scan, and MR imaging have increased our ability to detect and characterize focal liver lesions. Advances in the medical and surgical treatment of secondary liver tumors have continued to challenge these advances in radiology. A successful outcome depends on knowledge of the size and location of the tumor burden, and accurate radiologic assessment is crucial to identify those subgroups who may benefit from surgery and to prevent unnecessary radical surgery in those likely to gain only a short-term benefit.

CT scan of the liver

Since its inception, CT scan has had a dominant role in hepatic imaging. Recent advances including helical CT scan and bolus-triggered scan initiation software packages have had a significant impact. Issues regarding volume, rate of administration, and type of intravenous contrast are being distilled. Workstations for three-dimensional data reconstructions are producing images that compete with conventional angiography in certain areas, while angiographically assisted CT scan is being refined in others.

Difference in global hepatic enhancement assessed by dynamic CT in normal subjects and patients with hepatic metastases

PURPOSE

Our goal was to determine if there are differences in liver densitometry parameters using helical CT between normal subjects and subjects with liver metastases.

METHOD

One-hundred fifty subjects (64 with normal livers and 86 with CT-visible hepatic metastases) underwent dual phase helical scanning of the liver. Images were obtained in the "arterial" (early) and "venous" (late) phases of hepatic enhancement. Densitometry measurements were obtained from the liver (distinct from obvious lesions or vessels) and aorta at 25, 40, 75, and 90 s. Enhancement values at the same time points were calculated in 73 subjects in whom noncontrast images of the liver were available. A peak liver densitometry value was also determined. Several ratios were determined for each time point: the liver/aortic ratio (L/A), liver/liver peak ratio (L/P), liver enhancement/aortic enhancement ratio (LE/AE), and liver enhancement/liver peak enhancement ratio (LE/LPE). The degree of tumor burden in the hepatic metastatic group was assessed in each case.

RESULTS

Values for L/A, L/P, LE/AE, and LE/LPE at 25 and 40 s were significantly (p < 0.05) higher in the liver metastases group than the normal liver group. Enhancement ratios were even more elevated in breast cancer, which can have hypervascular metastases. These CT parameters did not show significant differences when analyzed according to the degree of hepatic metastatic tumor burden. All densitometry parameters and ratios obtained at 75 and 90 s were not significantly different between the two groups.

CONCLUSION

In the early phase of bolus intravenous contrast agent administration, the visually normal portion of the liver parenchyma in patients with hepatic metastases enhances to a greater degree than the liver in normal subjects. This may reflect generalized increased hepatic arterial flow in tumor-bearing livers and has the potential to increase the sensitivity of CT for detection of hepatic metastases.

A contrast agent delivery nomogram for hepatic spiral CT

PURPOSE

A nomogram for hepatic spiral CT (SCT) was constructed based on randomization of patients into a prospective study using four different injection protocols. Its utility in a separate prospective randomized trial was subsequently evaluated in a new group of patients.

METHODS

Thirty-nine patients randomized into four groups underwent SCT (Somatom-Plus S; 24 s exposure, 10 mm collimation, 10 mm/s) using 90 ml Omnipaque 240 (22 g I) at 2.5, 4, 5, or 6 ml/s. Peak and mean aortic and liver enhancement and time to peaks were measured and correlated with patients' age, weight, dose, rate, and contrast agent concentration, and a nomogram was constructed. In the validation experiment, 20 new patients were randomized to nomogram-guided and control groups for contrast dose administration during SCT. All patients underwent SCT (Somatom-Plus S; 32 s exposure, 10 mm collimation, 10 mm/s) using 90 ml Omnipaque 240 or 140 ml Hypaque 60 at 1.5-6 ml/s. Peak and mean aortic and liver enhancement and time to peaks were measured and correlated with patients' age, weight, dose, rate, and contrast agent concentration. Mean and peak aortic and hepatic enhancements were measured and rated by three blinded reviewers.

RESULTS

Peak hepatic enhancement occurred 32 s after termination of contrast bolus administration in all groups. Correlation between the predicted and actual enhancement was very good (r = 0.7-0.9). Ninety-eight percent of the nomogram-guided group had optimal timing and utilized 10% less contrast agent than the control group.

CONCLUSION

The phenomenon of peak hepatic enhancement occurring 32 s after the termination of contrast bolus regardless of injection rate may be of use in a nomogram for optimal contrast delivery for hepatic SCT.